about
The eEF1A Proteins: At the Crossroads of Oncogenesis, Apoptosis, and Viral InfectionsPolymeric micelles for apoptosis-targeted optical imaging of cancer and intraoperative surgical guidanceMolecular Insights into Microbial -Glucuronidase Inhibition to Abrogate CPT-11 ToxicityUse of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinicMolecular targeted therapy for the treatment of gastric cancerNew perspectives on targeted therapy in ovarian cancerProteomics of ovarian cancer: functional insights and clinical applicationsResveratrol inhibits cisplatin-induced epithelial-to-mesenchymal transition in ovarian cancer cell linesRetrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer.Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancersAberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancerThe role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trialsToxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer: A network meta-analysis.Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth.Effect of BRCA1 on epidermal growth factor receptor in ovarian cancer.Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic reviewIdentification of a six-lncRNA signature associated with recurrence of ovarian cancer.The multiple facets of drug resistance: one history, different approaches.Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer.Polyploid giant cancer cells with budding and the expression of cyclin E, S-phase kinase-associated protein 2, stathmin associated with the grading and metastasis in serous ovarian tumor.Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers.Molecular insights into the anti-cancer properties of traditional Tibetan medicine Yukyung KarneInduction of autophagy contributes to cisplatin resistance in human ovarian cancer cells.Intra-peritoneal hyperthermia combining α-galactosylceramide in the treatment of ovarian cancer.Y-box binding protein 1 enhances DNA topoisomerase 1 activity and sensitivity to camptothecin via direct interaction.Lack of association between MTHFD1 G401A polymorphism and ovarian cancer susceptibility.Proteomic identification of fucosylated haptoglobin alpha isoforms in ascitic fluids and its localization in ovarian carcinoma tissues from Mexican patients.Eradication of Human Ovarian Cancer Cells by Transgenic Expression of Recombinant DNASE1, DNASE1L3, DNASE2, and DFFB Controlled by EGFR Promoter: Novel Strategy for Targeted Therapy of Cancer.Glucocorticoid receptor repression mediated by BRCA1 inactivation in ovarian cancerExpression of BAF57 in ovarian cancer cells and drug sensitivity.Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian CancerHuman mesenchymal stroma/stem cells exchange membrane proteins and alter functionality during interaction with different tumor cell linesInvestigating impact of Vascular Endothelial Growth Factor Polymorphisms in Epithelial Ovarian Cancers: A Study in the Indian PopulationNanoparticle-induced intraperitoneal hyperthermia and targeted photoablation in treating ovarian cancer.MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting MyD88Overexpression of TMEM158 contributes to ovarian carcinogenesis.Lysophosphatidic Acid Initiates Epithelial to Mesenchymal Transition and Induces β-Catenin-mediated Transcription in Epithelial Ovarian Carcinoma.Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian CancerMicroRNA-532 and microRNA-3064 inhibit cell proliferation and invasion by acting as direct regulators of human telomerase reverse transcriptase in ovarian cancer.Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study.
P2860
Q26825635-175D992A-0089-42BF-B8B4-4B1D4A40951DQ27319594-ABA8A959-6A67-4497-9A70-9C17FF7ECB05Q27678202-1A80F98A-3718-46DC-B804-5725FF05714EQ28071541-9C0EEF1F-FB62-4CD5-9356-147B6FB4C174Q28072433-E8C72ADC-134E-4FF6-9304-FBCF59B26BC0Q28082524-CFB16769-5C2B-437C-8567-4C380836F6D9Q28082632-334063E7-83C6-4CA8-83AF-9974C90CDE4AQ28539044-79DF2A2B-BEC4-45DF-AECB-C329EEC2B4E3Q28539509-40405C65-25DF-477C-9FA6-52126F1188A5Q28542563-B0F8231D-B7FC-47C3-9142-DC9F7456B2C9Q28543351-F535B2F9-859C-43D5-AA4A-60375D75A42DQ33409319-ECC01383-4FF6-4444-B4D8-F8754DC78719Q33438344-B867417E-830E-4816-B8E9-BE6883F411E4Q33588273-100FD0AE-17DE-4C7C-A0EC-FB6D9331726CQ33643669-D02611FD-79DF-46D4-B367-82C53A2E98DCQ33662162-D8FDD40D-EE7F-408A-98FA-3857F3E98EA5Q33677576-C8342BBC-2B9C-4FFB-8572-2173086B91E0Q33697116-A15953E9-5D6C-46F3-814B-56E6B400F747Q33716280-B065251A-0B9D-43A8-94CE-2E58F98A9390Q34062677-94149924-B4F8-4D8F-8361-D2B11AAA1877Q34234110-8AA49E8C-11AF-4453-86BB-D35C36801FDFQ34340137-FC23B496-9BAA-4628-B23C-E2BAA781644EQ34540874-F4EA8F88-2BDD-4FFF-8D55-9F0E1B41FBADQ34919851-A2EC94E4-9279-4EFC-A222-3215CD831DD4Q35021157-25634920-580F-4795-9E13-D5A3BF45C905Q35056269-566A5528-D1FF-45CF-BF1C-57C4EC85539BQ35104034-B44BDAA3-BB11-494B-A225-6F70A5C1EF87Q35109273-B3AC89A5-E493-4EA9-8BD7-45ACAF72F194Q35120801-A17F2E54-0CB0-4585-B460-104F916C6031Q35538429-757248E1-AA71-4320-9CE7-49AC2ADE2D9AQ35563128-22B238B0-380E-4924-8723-98864F053256Q35586175-834EF4B2-6B2E-47D3-B781-C5195141348DQ35687160-4D30EBA1-4A24-4A8F-A246-4A69C1AF5D61Q35759283-53E73F7E-BB1A-463C-85E3-6011EFC9E036Q35902797-A2A2C1FB-0975-4710-9346-63CB218DD445Q35913762-D4934184-E8C5-4E75-814F-B5B2486A4E37Q36065252-27D6F873-4CA1-4730-8CE3-4D0FCD921430Q36167088-137955FD-BD79-491D-A50B-230E4536FAD3Q36307498-9DCA6022-00B6-4219-BDBE-6C2E690CD2CFQ36369334-39FC340C-B479-4D21-B9D4-0E64BB3C33B8
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Therapeutic strategies in epithelial ovarian cancer.
@ast
Therapeutic strategies in epithelial ovarian cancer.
@en
type
label
Therapeutic strategies in epithelial ovarian cancer.
@ast
Therapeutic strategies in epithelial ovarian cancer.
@en
prefLabel
Therapeutic strategies in epithelial ovarian cancer.
@ast
Therapeutic strategies in epithelial ovarian cancer.
@en
P2093
P2860
P921
P356
P1476
Therapeutic strategies in epithelial ovarian cancer.
@en
P2093
Takayuki Enomoto
Tetsuji Naka
Yutaka Ueda
P2860
P2888
P356
10.1186/1756-9966-31-14
P5008
P577
2012-02-13T00:00:00Z
P5875
P6179
1037596000